Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
18 - Managing acute vascular events in patients with myeloproliferative neoplasms
Published online by Cambridge University Press: 05 March 2016
Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Managing Myeloproliferative NeoplasmsA Case-Based Approach, pp. 160 - 171Publisher: Cambridge University PressPrint publication year: 2016
References
Marchioli, R, Finazzi, G, Landolfi, R, Kutti, J, Gisslinger, H, Patrono, C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. Journal of Clinical Oncology. 2005;23(10):2224–32.CrossRefGoogle Scholar
Barbui, T, Carobbio, A, Cervantes, F, Vannucchi, AM, Guglielmelli, P, Antonioli, E, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 2010;115(4):778–82.CrossRefGoogle ScholarPubMed
Montanaro, M, Latagliata, R, Cedrone, M, Spadea, A, Rago, A, Di Giandomenico, J, et al. Thrombosis and survival in essential thrombocythemia: a regional study of 1144 patients. American Journal of Hematology. 2014;89(5):542–6.CrossRefGoogle Scholar
Besses, C, Cervantes, F, Pereira, A, Florensa, L, Sole, F, Hernandez-Boluda, JC, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia. 1999;13(2):150–4.CrossRefGoogle Scholar
Jantunen, R, Juvonen, E, Ikkala, E, Oksanen, K, Anttila, P, Ruutu, T. The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia. Annals of Hematology. 2001;80(2):74–8.CrossRefGoogle ScholarPubMed
Landolfi, R, Di Gennaro, L, Barbui, T, De Stefano, V, Finazzi, G, Marfisi, R, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109(6):2446–52.CrossRefGoogle Scholar
Carobbio, A, Antonioli, E, Guglielmelli, P, Vannucchi, AM, Delaini, F, Guerini, V, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. Journal of Clinical Oncology. 2008;26(16):2732–6.CrossRefGoogle ScholarPubMed
Barbui, T, Finazzi, G, Falanga, A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122(13):2176–84.CrossRefGoogle ScholarPubMed
Klampfl, T, Gisslinger, H, Harutyunyan, AS, Nivarthi, H, Rumi, E, Milosevic, JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. New England Journal of Medicine. 2013;369(25):2379–90.CrossRefGoogle ScholarPubMed
Rotunno, G, Mannarelli, C, Guglielmelli, P, Pacilli, A, Pancrazzi, A, Pieri, L, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2013;123(10):1552–5.Google ScholarPubMed
Panova-Noeva, M, Marchetti, M, Buoro, S, Russo, L, Leuzzi, A, Finazzi, G, et al. JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood. 2011;118(9):2599–601.CrossRefGoogle ScholarPubMed
Etheridge, SL, Roh, ME, Cosgrove, ME, Sangkhae, V, Fox, NE, Chen, J, et al. JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(6):2295–300.Google ScholarPubMed
Coucelo, M, Caetano, G, Sevivas, T, Almeida Santos, S, Fidalgo, T, Bento, C, et al. JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients. International Journal of Hematology. 2013;99(1):32-40.Google ScholarPubMed
Antonioli, E, Guglielmelli, P, Poli, G, Bogani, C, Pancrazzi, A, Longo, G, et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica. 2008;93(1):41–8.CrossRefGoogle ScholarPubMed
Nielsen, C, Birgens, HS, Nordestgaard, BG, Bojesen, SE. Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population. British Journal of Haematology. 2013;160(1):70–9.CrossRefGoogle ScholarPubMed
Lussana, F, Caberlon, S, Pagani, C, Kamphuisen, PW, Buller, HR, Cattaneo, M. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thrombosis Research. 2009;124(4):409–17.CrossRefGoogle ScholarPubMed
Barbui, T, Finazzi, G, Carobbio, A, Thiele, J, Passamonti, F, Rumi, E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128–33; quiz 252.CrossRefGoogle ScholarPubMed
Marchioli, R, Finazzi, G, Specchia, G, Cacciola, R, Cavazzina, R, Cilloni, D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. New England Journal of Medicine. 2013;368(1):22–33.CrossRefGoogle ScholarPubMed
Landolfi, R, Marchioli, R, Kutti, J, Gisslinger, H, Tognoni, G, Patrono, C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. New England Journal of Medicine. 2004;350(2):114–24.CrossRefGoogle ScholarPubMed
Squizzato, A, Romualdi, E, Passamonti, F, Middeldorp, S. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. Cochrane Database of Systematic Reviews. 2013;4:CD006503.Google Scholar
Alvarez-Larran, A, Cervantes, F, Pereira, A, Arellano-Rodrigo, E, Perez-Andreu, V, Hernandez-Boluda, JC, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010;116(8):1205–10; quiz 387.CrossRefGoogle ScholarPubMed
Cortelazzo, S, Finazzi, G, Ruggeri, M, Vestri, O, Galli, M, Rodeghiero, F, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. New England Journal of Medicine. 1995;332(17):1132–6.CrossRefGoogle Scholar
Barosi, G, Mesa, R, Finazzi, G, Harrison, C, Kiladjian, JJ, Lengfelder, E, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013;121(23):4778–81.CrossRefGoogle ScholarPubMed
Kiladjian, JJ, Besses, C, Griesshammer, M, Gugliotta, L, Harrison, C, Coll, R, et al. Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS study. Clinical Drug Investigation. 2013;33(1):55–63.CrossRefGoogle ScholarPubMed
Harrison, CN, Campbell, PJ, Buck, G, Wheatley, K, East, CL, Bareford, D, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. New England Journal of Medicine. 2005;353(1):33–45.CrossRefGoogle ScholarPubMed
Gisslinger, H, Gotic, M, Holowiecki, J, Penka, M, Thiele, J, Kvasnicka, HM, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial. Blood. 2013;121(10):1720–8.CrossRefGoogle ScholarPubMed
Quintas-Cardama, A, Kantarjian, H, Manshouri, T, Luthra, R, Estrov, Z, Pierce, S, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. Journal of Clinical Oncology. 2009;27(32):5418–24.CrossRefGoogle ScholarPubMed
Elliott, MA, Tefferi, A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. British Journal of Haematology. 2005;128(3):275–90.CrossRefGoogle ScholarPubMed
Kiladjian, JJ, Chevret, S, Dosquet, C, Chomienne, C, Rain, JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. Journal of Clinical Oncology. 2011;29(29):3907–13.CrossRefGoogle ScholarPubMed
Verstovsek, S, Passamonti, F, Rambaldi, A, Barosi, G, Rosen, PJ, Rumi, E, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014;120(4):513–20.CrossRefGoogle ScholarPubMed
McMahon, B, Stein, BL. Thrombotic and bleeding complications in classical myeloproliferative neoplasms. Seminars in Thrombosis and Hemostasis. 2013;39(1):101–11.Google ScholarPubMed
Barbui, T, Carobbio, A, Finazzi, G, Vannucchi, AM, Barosi, G, Antonioli, E, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica. 2011;96(2):315–18.CrossRefGoogle ScholarPubMed
Panova-Noeva, M, Marchetti, M, Russo, L, Tartari, CJ, Leuzzi, A, Finazzi, G, et al. ADP-induced platelet aggregation and thrombin generation are increased in essential thrombocythemia and polycythemia vera. Thrombosis Research. 2013;132(1):88–93.CrossRefGoogle ScholarPubMed
De Grandis, M, Cambot, M, Wautier, MP, Cassinat, B, Chomienne, C, Colin, Y, et al. JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway. Blood. 2013;121(4):658–65.CrossRefGoogle ScholarPubMed
Carobbio, A, Finazzi, G, Guerini, V, Spinelli, O, Delaini, F, Marchioli, R, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2007;109(6):2310–13.CrossRefGoogle ScholarPubMed
Trelinski, J, Wierzbowska, A, Krawczynska, A, Sakowicz, A, Pietrucha, T, Smolewski, P, et al. Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers. International Journal of Hematology. 2010;91(5):792–8.CrossRefGoogle ScholarPubMed
Marchetti, M, Castoldi, E, Spronk, HM, van Oerle, R, Balducci, D, Barbui, T, et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood. 2008;112(10):4061–8.CrossRefGoogle ScholarPubMed
De Stefano, V, Za, T, Rossi, E, Vannucchi, AM, Ruggeri, M, Elli, E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008;93(3):372–80.CrossRefGoogle ScholarPubMed
Carobbio, A, Thiele, J, Passamonti, F, Rumi, E, Ruggeri, M, Rodeghiero, F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117(22):5857–9.CrossRefGoogle Scholar
Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Annals of Internal Medicine. 1995;123(9):656–64.Google Scholar
Posfai, E, Marton, I, Szoke, A, Borbenyi, Z, Vecsei, L, Csomor, A, et al. Stroke in essential thrombocythemia. Journal of the Neurological Sciences. 2014;336(1–2):260–2.CrossRefGoogle ScholarPubMed
Smalberg, JH, Arends, LR, Valla, DC, Kiladjian, JJ, Janssen, HL, Leebeek, FW. Myeloproliferative neoplasms in Budd–Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012;120(25):4921–8.CrossRefGoogle ScholarPubMed
Reikvam, H, Tiu, RV. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukemia. 2012;26(4):563–71.CrossRefGoogle ScholarPubMed
Gangat, N, Wolanskyj, AP, Tefferi, A. Abdominal vein thrombosis in essential thrombocythemia: prevalence, clinical correlates, and prognostic implications. European Journal of Haematology. 2006;77(4):327–33.CrossRefGoogle ScholarPubMed
Condat, B, Pessione, F, Hillaire, S, Denninger, MH, Guillin, MC, Poliquin, M, et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology. 2001;120(2):490–7.CrossRefGoogle ScholarPubMed
Barbui, T, Barosi, G, Birgegard, G, Cervantes, F, Finazzi, G, Griesshammer, M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. Journal of Clinical Oncology. 2011;29(6):761–70.CrossRefGoogle ScholarPubMed
Malkowski, P, Pawlak, J, Michalowicz, B, Szczerban, J, Wroblewski, T, Leowska, E, et al. Thrombolytic treatment of portal thrombosis. Hepato-gastroenterology. 2003;50(54):2098–100.Google ScholarPubMed
Vantroyen, B, Vanstraelen, D. Management of essential thrombocythemia during pregnancy with aspirin, interferon alpha-2a and no treatment. A comparative analysis of the literature. Acta Haematologica. 2002;107(3):158–69.CrossRefGoogle ScholarPubMed
Passamonti, F, Randi, ML, Rumi, E, Pungolino, E, Elena, C, Pietra, D, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood. 2007;110(2):485–9.CrossRefGoogle ScholarPubMed
Gangat, N, Wolanskyj, AP, Schwager, S, Tefferi, A. Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. European Journal of Haematology. 2009;82(5):350–3.CrossRefGoogle ScholarPubMed
Randi, ML, Bertozzi, I, Rumi, E, Elena, C, Finazzi, G, Vianelli, N, et al. Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. American Journal of Hematology. 2014;89(3):306–9.CrossRefGoogle ScholarPubMed
Guyatt, GH, Akl, EA, Crowther, M, Gutterman, DD, Schuunemann, HJ, et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):7S–47S.CrossRefGoogle ScholarPubMed
CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet. 1994;343(8898):619–29.Google Scholar
Griesshammer, M, Struve, S, Harrison, CM. Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe. Seminars in Thrombosis and Hemostasis. 2006;32(4):422–9.CrossRefGoogle ScholarPubMed
Passamonti, F, Rumi, E, Randi, ML, Morra, E, Cazzola, M. Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies. Journal of Thrombosis and Haemostasis. 2010;8(2):411–13.CrossRefGoogle ScholarPubMed
Liebelt, EL, Balk, SJ, Faber, W, Fisher, JW, Hughes, CL, Lanzkron, SM, et al. NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea. Birth Defects Research Part B, Developmental and Reproductive Toxicology. 2007;80(4):259–366.CrossRefGoogle Scholar
Melillo, L, Tieghi, A, Candoni, A, Radaelli, F, Ciancia, R, Specchia, G, et al. Outcome of 122 pregnancies in essential thrombocythemia patients: a report from the Italian registry. American Journal of Hematology. 2009;84(10):636–40.CrossRefGoogle ScholarPubMed
Bangerter, M, Guthner, C, Beneke, H, Hildebrand, A, Grunewald, M, Griesshammer, M. Pregnancy in essential thrombocythaemia: treatment and outcome of 17 pregnancies. European Journal of Haematology. 2000;65(3):165–9.CrossRefGoogle ScholarPubMed
Pagliaro, P, Arrigoni, L, Muggiasca, ML, Poggio, M, Russo, U, Rossi, E. Primary thrombocythemia and pregnancy: treatment and outcome in fifteen cases. American Journal of Hematology. 1996;53(1):6–10.3.0.CO;2-V>CrossRefGoogle ScholarPubMed
- 1
- Cited by